MedTrace Logo

Early Add-On Combination of GLP-1 Receptor Agonist and SGLT2 Inhibitor in People With Cardiovascular-Kidney-Metabolic Stage 2-3

NCT07465926 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 451036

Last updated 2026-03-12

No results posted yet for this study

Summary

This observational target-trial emulation study uses routinely collected electronic health record data from the TriNetX US Collaborative Network to compare early add-on treatment strategies in adults with obesity, type 2 diabetes, and cardiovascular-kidney-metabolic stage 2-3. The study evaluates outcomes among people who start a GLP-1 receptor agonist or an SGLT2 inhibitor and then, within 90 days, either add the alternate therapy, add a DPP-4 inhibitor or sulfonylurea, or do not receive early add-on treatment. The primary outcome is all-cause mortality within 36 months. Secondary outcomes include major adverse cardiovascular events and major adverse kidney events. Nonrandom treatment selection is addressed using propensity-score matching to estimate comparative risks and treatment effects.

Conditions

Interventions

DRUG

GLP-1 receptor agonist

Use of a glucagon-like peptide-1 receptor agonist as background therapy or add-on therapy in adults with obesity, type 2 diabetes, and cardiovascular-kidney-metabolic stage 2-3.

DRUG

SGLT2 inhibitor

Use of a sodium-glucose cotransporter-2 inhibitor as background therapy or add-on therapy in adults with obesity, type 2 diabetes, and cardiovascular-kidney-metabolic stage 2-3.

Sponsors & Collaborators

  • National Science and Technology Council, Taiwan

    collaborator OTHER_GOV

  • Chung Shan Medical University

    lead OTHER

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2026-01-31
Completion
2026-01-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07465926 on ClinicalTrials.gov